Deletion of the Carboxy-Terminus of Herpes Simplex Virus Type 1 (HSV-1) Glycoprotein B Does Not Affect Oligomerization, Heparin-Binding Activity, or Its Ability to Protect Against HSV Challenge

Arch Virol. 1996;141(6):1153-65. doi: 10.1007/BF01718618.

Abstract

A recombinant vaccinia virus designated VgBt which expresses a truncated secreted herpes simplex virus gB (gBt) was constructed and compared to V11gB, a vaccinia recombinant previously studied which expresses gB exclusively on the surface of infected cells. Indirect immunofluorescence assay (IFA) revealed that gBt was strongly associated with the surface of infected cells despite being released slowly into the cell culture medium. Both gB and gBt existed as oligomers, and both membrane bound and secreted forms of gBt exhibited heparin-binding activity. In protection studies VgBt and V11gB conferred equivalent protection against both homologous (HSV-1) and heterologous (HSV-2) challenge with HSV.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Animals
  • Antigens, Viral / genetics
  • Antigens, Viral / immunology
  • Antigens, Viral / metabolism
  • Disease Models, Animal
  • Female
  • Heparin / metabolism*
  • Herpes Simplex / immunology
  • Herpes Simplex / prevention & control*
  • Herpesvirus 1, Human / genetics
  • Herpesvirus 1, Human / immunology*
  • Humans
  • Mice
  • Mice, Inbred BALB C
  • Sequence Deletion
  • Structure-Activity Relationship
  • Vaccination
  • Vaccines, Synthetic / genetics
  • Vaccines, Synthetic / immunology
  • Vaccines, Synthetic / metabolism
  • Vaccinia virus / genetics
  • Vaccinia virus / immunology
  • Viral Envelope Proteins / genetics
  • Viral Envelope Proteins / immunology*
  • Viral Envelope Proteins / metabolism
  • Viral Vaccines / genetics
  • Viral Vaccines / immunology*
  • Viral Vaccines / metabolism

Substances

  • Antigens, Viral
  • Vaccines, Synthetic
  • Viral Envelope Proteins
  • Viral Vaccines
  • glycoprotein B, Simplexvirus
  • Heparin